Member Portal    
 
  Clinical
ALS Trials
Trials
Browse Recruiting Trials
Search for a Trial
Clinical Trial News
Clinical Trials 101
Questions about Clinical Research?
Contact an ALS Trial Liaison


Call or email us with your questions
about clinical research

(877) 458-0631
alstrials@partners.org
 

A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, & Pharmacokinetics of ISIS333611 Administered Intrathecally to Patients w Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutation

 
Study Focus:
This study will test the safety, tolerability, and pharmacokinetics of single doses of ISIS 333611 administered as 12-hour intrathecal infusions.
Disease:
Amyotrophic Lateral Sclerosis (ALS), Familial ALS
Study Category:
Drug Trial
Study Status:
Closed
Study Results:
A total of 32 doses were given to 21 individuals with SOD1 ALS (7 subjects were dosed 2 times and 2 subjects were dosed 3 times). Results indicate that ISIS 333611 was well tolerated. No safety or tolerability concerns related to ISIS 333611 were identified. Drug levels in the spinal fluid and blood corresponded well with the predicted levels based on preclinical testing.
Phase:
Phase I
Type:
Interventional Trial
with active agents/drugs & a placebo
Funding Source:
Isis Pharmaceuticals, Inc.
Study Chair(s)/Principal Investigator(s):
Merit Cudkowicz MD, MSc, (Massachusetts General Hospital)
Timothy Miller MD, PhD, (Washington University)
Clinicaltrials.gov ID:
NCT01041222
NEALS Affiliated?
Yes
Study Summary:
This study will test the safety, tolerability, and pharmacokinetics of single doses of ISIS 333611 administered as 12-hour intrathecal infusions. Four dose levels (0.15, 0.5, 1.5 and 3 mg) will be evaluated sequentially. The volume of the infusion is 0.25 mL/12 hours. Each dose level will be studied in a cohort of 8 patients where 6 are randomized to active treatment with ISIS 333611 and 2 are randomized to placebo.
Participant Duration:
Total enrollment time for this study is about 8 weeks. The screening visit will last approximately 2-4 hours. During the treatment phase of the study, you will be admitted to the hospital for the temporary intrathecal infusion procedure for about two days. After the treatment phase, there is a 4 week follow up period with two in-clinic visits (each visit is about 2-3 hours) and one telephone contact/visit (about 30 minutes).
# of Subjects:
4 cohorts of 8 patients each, total 32 patients
Enrollment Start Date:
01/01/2010
Enrollment End Date:
12/01/2011
Posting Last Modified Date:
12/01/2011
Date Study Added to alsconsortium.org:
11/02/2011
Eligibility Criteria
Gender:
Male & Female
Minimum Age:
18
Min Vital Capacity (% predicted normal):
50%
Time since Symptom Onset:
Not applicable
Time since Diagnosis:
Not applicable
Can participants use Riluzole?
Yes
Coordinating Center
Contact Information
Katy Mahoney
kmahoney17@partners.org
617-643-7434
Massachusetts General Hospital
149 13th Street
Charlestown, Massachusetts 02129
UNITED STATES
Other Eligibility Criteria:
If taking riluzole, patients must be on stable dosage for at least 30 days prior to starting the study and expect to remain at that dosage until the end of the study.

Site Contact Information

 (Please click to show/hide)
 
For Patients & Families
Educational Webinars
Online NEALS Resources
Other Resources
Contact a Disease Specialist
Clinical Research Blog

For Researchers
Become a NEALS member
Post an ALS Clinical Trial
NEALS CRO Capabilities
Annual NEALS Meeting
NEALS Samples
NEALS Historical Data
ALS Trials
Browse Recruiting Trials
Search for a Trial
Clinical Trial News
Clinical Trials 101

Get Involved
Donate samples
Donate to our Clinical Research
About Us
Our Mission
Our Structure
Our Research
NEALS Members
Motor Neuron Disease
Connect with us: Member Portal       Donate Now!       Help       Sitemap       Contact Us